GLP-1 and Pregnancy What Women Should Know | MetaGO

GLP-1 and Pregnancy, Fertility and Contraception: What Women Need to Know

Table of Contents

Quick Answer
Do not use GLP-1 medicines during pregnancy. Stop semaglutide at least 2 months, and tirzepatide at least 1 month, before trying to conceive. On tirzepatide, back up the pill for 4 weeks after starting and after each dose increase. Weight loss can restart ovulation, so use reliable contraception. Pregnant unexpectedly? Stop and call your doctor that day.

GLP-1 medicines don’t belong in pregnancy. They can, however, help a woman reach a healthier pregnancy, especially if PCOS or excess weight has been keeping her from ovulating.

The working rules are short. Use dependable contraception while you’re on treatment. Stop well before you start trying, with the timing set by the molecule you take.

And if a pregnancy surprises you, stop the injection and speak to your doctor that same day.

The rest of this guide explains why, with the Indian details that most international articles skip: the generic brands now on our shelves, the contraceptives Indian women actually use, and what PCOS looks like here.

GLP-1s and Pregnancy: What the Labels Say

Prescribing information for GLP-1 medicines carries the same core message: they are not for use in pregnancy. That caution rests mainly on animal studies, because pregnant women are usually kept out of drug trials.

The Wegovy prescribing information describes what happened when semaglutide was given to pregnant rats, rabbits and monkeys: early pregnancy loss, structural abnormalities and slower growth in the offspring.

The detail most articles miss is that these effects showed up alongside marked weight loss, or poor weight gain, in the mothers. That points to the real problem.

Pregnancy is the one stage of adult life where losing weight brings no benefit. A growing baby needs the mother to gain a healthy amount, even if she started with obesity, and a medicine designed to curb appetite works against that.

So the rule covers the whole class: semaglutide in every form (Ozempic, Wegovy, Rybelsus and the generics launched in India since March 2026), tirzepatide (Mounjaro) and liraglutide (Saxenda, Victoza).

How Long to Stop Before Conception

The waiting period follows how long each molecule stays in your blood (its half-life). Weekly injections are built to linger, so they need the longest gap.

Semaglutide has a half-life of about one week, and the Wegovy label notes it stays in circulation for roughly 5 to 7 weeks after the last dose. Picture a full matka that loses half its water every week: after six weeks only a few sips remain, and the two-month rule covers that tail.

Medicine (molecule)Common names in IndiaApproximate half-lifeStop before trying to conceive
Semaglutide injectionOzempic, Wegovy, generic semaglutide brandsAbout 1 weekAt least 2 months
Oral semaglutideRybelsusAbout 1 weekAt least 2 months
TirzepatideMounjaroAbout 5 daysAt least 1 month (UK and EU labels); the US label sets no fixed washout
LiraglutideSaxenda, VictozaAbout 13 hoursWhen you start trying; no long washout needed

Two months is roughly two menstrual cycles. If your cycles run long, as they often do with PCOS, count weeks on a calendar rather than periods.

One India-specific trap: since the semaglutide patent expired here in March 2026, dozens of brands sell the same molecule under different names. The washout follows the molecule, not the brand, so check the generic name printed on your pen or carton.

GLP-1s and Fertility

Here is the counterintuitive part. Medicines you must avoid in pregnancy can make pregnancy more likely.

Excess body fat, especially at the waist, keeps insulin levels high. High insulin nudges the ovaries to make more male hormones (androgens), and that hormonal noise can stop an egg being released each month.

Bring weight and insulin down and the ovaries often restart regular ovulation. For a woman who hasn’t ovulated reliably in years, that can happen within months, sometimes before contraception is even on her mind.

The best evidence comes from PCOS. A 2023 meta-analysis in BMC Endocrine Disorders pooled 11 randomised trials with 840 women and found those on GLP-1 medicines were about 1.7 times as likely to conceive naturally, with more regular periods too.

Keep that number in proportion. The trials were small and mostly used older molecules such as liraglutide and exenatide, and IVF pregnancy rates showed no clear difference.

‘Ozempic babies’ and improved ovulation

“Ozempic babies” is the internet’s name for pregnancies that arrive unplanned while a woman is on a GLP-1 medicine. The stories spread fastest among women who had been told they would struggle to conceive.

Nobody has counted these pregnancies properly, so treat the trend as real but unmeasured.

Two explanations hold up. Ovulation can return as weight falls, and the pill can be less reliable during the early weeks of tirzepatide or after bouts of vomiting. A history of irregular periods is not a form of contraception.

Contraception on a GLP-1

Most contraception works normally on GLP-1 medicines. A Copper-T, a hormonal IUD, an implant, the Antara injection and condoms don’t depend on your stomach, so slower digestion can’t touch them.

The pill is where questions start. GLP-1 medicines slow how quickly the stomach empties (delayed gastric emptying), which can change how a tablet is absorbed.

For semaglutide, interaction studies in the Wegovy prescribing information found no meaningful change in levels of a standard combined pill. The bigger everyday risk is a side effect.

In Wegovy’s trials, 44 in 100 adults had nausea, 30 had diarrhoea and 24 vomited, mostly while the dose was being increased. These are the most common Ozempic and Wegovy side effects, and a pill vomited soon after swallowing may not be absorbed. Follow the missed-pill instructions on your pack and tell your doctor if it keeps happening.

Tirzepatide and oral contraceptives

Tirzepatide is the GLP-1 with formal contraception advice. Its slowing of the stomach is strongest after the first dose and after each step up, which can blunt absorption of hormonal pills.

Regulators spell out the fix. A safety update from Australia’s Therapeutic Goods Administration, matching the Mounjaro labels elsewhere, advises women on the pill to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and 4 weeks after every dose increase.

The clock resets with every step up. Mounjaro doses usually rise every 4 weeks, so backup contraception can run for months, which is why many doctors suggest a Copper-T, hormonal IUD or implant from the start.

Two Indian options deserve a mention. Chhaya (centchroman), the weekly non-hormonal pill offered through the national family planning programme, and emergency contraceptive pills are also absorbed through the gut. Neither has been studied with tirzepatide, so ask your doctor before relying on them.

If You Become Pregnant While Taking One

Stop the medicine and call your doctor the same day. Don’t wait for your next scheduled dose to decide.

Then take a breath, because the human data so far are reassuring. The largest study to date, by Cesta and colleagues in JAMA Internal Medicine, followed the babies of women with type 2 diabetes across four Nordic countries, the US and Israel.

Among 938 babies exposed to a GLP-1 medicine at conception or in the first trimester, major birth defects were no more common than in babies whose mothers used insulin. The rate was about 8 in 100 in both groups, higher than in the general population because diabetes itself raises the risk.

It is one study, focused on birth defects in women with diabetes, so it settles less than the headlines suggest.

What follows is ordinary antenatal care. Your doctor will date the pregnancy, plan the routine scans, start folic acid if you aren’t already taking it and, if the medicine was for diabetes, move you to options used in pregnancy such as insulin.

Breastfeeding

Prescribing information does not recommend GLP-1 medicines while breastfeeding, mainly because the data are thin. The first human evidence, though, is encouraging.

A 2024 study in Nutrients tested breast milk from eight mothers using semaglutide injections and found no detectable drug in any sample. Even in a worst-case calculation, the baby’s share of the dose (relative infant dose) came to about 1.26%, far below the 10% level usually treated as a concern.

Eight women is a very small group. Oral semaglutide is a separate case, because the absorption enhancer in the tablet may pass into milk.

The more practical worry is milk supply. Exclusive breastfeeding can demand up to about 500 extra calories a day, roughly a full extra meal, and that is why many Indian families lean on panjiri and gond ke laddoo after delivery. An appetite-suppressing medicine pulls the other way.

Whether and when to restart treatment is a decision to make with your doctor once you know how you plan to feed your baby.

PCOS, Fertility and GLP-1s

PCOS is where every thread of this guide meets, and it is far more common in India than most women realise. The ICMR-PCOS study in JAMA Network Open examined 9,824 women aged 18 to 40 across the country and found about 1 in 5 (19.6%) had PCOS by the widely used Rotterdam criteria.

The same study found the most common pattern in India combined excess male hormones (acne, facial hair) with polycystic-looking ovaries while periods stayed fairly regular (phenotype C). Regular periods, in other words, don’t rule PCOS out.

Weight drives PCOS harder in South Asian women, who tend to carry more abdominal fat at lower body weights. Indian guidelines therefore flag excess weight from a BMI of 23 rather than 25, and abdominal obesity from a waist of 80 cm in women.

PCOS treatment usually starts with lifestyle change. Metformin has long been the standard medicine for PCOS-related insulin resistance, and it is one of the few diabetes medicines also used in pregnancy.

GLP-1 medicines work on the same insulin problem while also lowering appetite and weight, which is why doctors increasingly use them, sometimes alongside metformin, to restore ovulation before a planned pregnancy.

The order matters: treat, regain regular cycles, stop the GLP-1 for the right washout, then try.

Planning Pregnancy With Your Doctor

A planned pregnancy on a GLP-1 runs on a simple timeline. The steps below assume semaglutide; for tirzepatide the washout is one month.

WhenWhat to do
As soon as you want a babyTell your doctor and agree on a last-dose date based on your molecule.
Before the last dosePlan how to hold your weight steady once appetite returns. Keep using contraception.
2 months before tryingTake your last semaglutide dose. No tapering is needed.
During the washoutContinue contraception, start folic acid as advised, and complete routine checks such as blood sugar.
Once the window has passedStart trying, and book an early antenatal visit when you conceive.

Expect some hunger to come back during the washout. That is the medicine leaving your system, not a failure of willpower, and a plan built on the meals you already eat makes it easier to hold your ground.

In a doctor-led programme, wanting to conceive is a recognised reason to pause treatment, with the doctor guiding the wind-down and staying in touch through it.

Conclusion
GLP-1 medicines and pregnancy don’t mix, yet the same medicines can clear the way to a healthier one, particularly with PCOS. Stop semaglutide at least two months and tirzepatide at least one month before trying, back up the pill during tirzepatide dose changes, and treat a surprise pregnancy as a same-day call to your doctor rather than a crisis.

FAQ

1. Can I take a GLP-1 while pregnant?

No. GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and the newer semaglutide generics, are not meant for use in pregnancy and are stopped once pregnancy is recognised. Animal studies showed harm to developing offspring, human data are limited, and pregnancy is a time when a healthy amount of weight gain is needed, not weight loss.

2. How long before trying to conceive should I stop?

For semaglutide (Ozempic, Wegovy, Rybelsus and generics), stop at least 2 months before trying. For tirzepatide (Mounjaro), UK and EU labels advise at least 1 month. Liraglutide (Saxenda, Victoza) clears within days, so it is stopped when you start trying. Agree the exact date with your doctor.

3. Do GLP-1s improve fertility?

They can, mainly in women whose weight and insulin resistance have stopped regular ovulation, as often happens with PCOS. A 2023 meta-analysis of 11 trials found women with PCOS on GLP-1 medicines were about 1.7 times as likely to conceive naturally. The medicine is still stopped before trying to conceive.

4. Do they make oral contraceptives less effective?

Tirzepatide (Mounjaro) can. Use a non-oral method, or add condoms, for 4 weeks after starting and for 4 weeks after every dose increase. Semaglutide showed no meaningful effect on the pill in studies, but vomiting or diarrhoea from any GLP-1 can stop a pill being absorbed.

5. What if I become pregnant while taking one?

Stop the medicine and call your doctor the same day. The largest study so far, in women with type 2 diabetes, found no rise in major birth defects among babies exposed to GLP-1 medicines early in pregnancy compared with insulin. Your doctor will then plan routine antenatal care and, if you have diabetes, switch your treatment.

Medical Disclaimer
This article is for general education only and is not a substitute for medical advice, diagnosis or treatment. GLP-1 medicines are prescription-only and must be started, adjusted and stopped under the supervision of a qualified doctor. If you are pregnant, planning a pregnancy or breastfeeding, speak to your doctor before making any change to your medicines.
  1. U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets: full prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
  2. Kommu S, Whitfield P. Semaglutide. StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2024 Feb 11. https://www.ncbi.nlm.nih.gov/books/NBK603723/
  3. Therapeutic Goods Administration (Australia). Updated contraception advice for Mounjaro (tirzepatide). Safety update. https://www.tga.gov.au/news/safety-updates/updated-contraception-advice-mounjaro-tirzepatide
  4. Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Internal Medicine. 2024;184(2):144-152. doi: 10.1001/jamainternmed.2023.6663
  5. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders. 2023;23:245. doi: 10.1186/s12902-023-01500-5
  6. Ganie MA, Chowdhury S, Malhotra N, et al. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. JAMA Network Open. 2024;7(10):e2440583. doi: 10.1001/jamanetworkopen.2024.40583
  7. Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024;16(17):2886. doi: 10.3390/nu16172886
Picture of Dr. Kaushal Patel

Dr. Kaushal Patel

MBBS, MD (Medicine), [Cardiologist Specialist in Diabetology & Obesity Management]